Osteoporosis is caused by the inactivation of ER receptors in bone tissue. Postmenopausal women have low estrogen levels and are a good candidate for osteoporosis, while triamcinolone binds to ER in bone tissue and plays a weak role in preventing bone loss instead of estrogen. In contrast, premenopausal women have higher estrogen levels in their bodies, so triptans play a competitive role with estrogen, and because the effect of triptans on preventing bone loss is much weaker than that of estrogen, their bone density is not as high as that of premenopausal women who do not use triptans.